Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to discuss its new provisional patent application with the United States Patent and Trademark Office that extends its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs. Lanthier and Araujo say the most recent application covers a “comprehensive range” of next generation drug candidates, as well as their related chemical process synthesis, composition of matter and therapeutic uses.
Mindset Pharma files newest US patent application for its Family 4 DMT compounds
